1	Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection
2 3	Oluwasanmi O. Adenaiye, M.B.B.S., M.S.ª, Jianyu Lai, B.Med., M.P.H. ^b , P. Jacob Bueno de Mesquita,
4	Ph.D. ^a , Filbert Hong, Ph.D. ^a , Somayeh Youssefi, Ph.D. ^a , Jennifer German, Ph.D. ^a , SH. Sheldon Tai,
5	Ph.D. ^a , Barbara Albert, M.D., M.P.H. ^a , Maria Schanz, B.A., B.S. ^a , Stuart Weston, Ph.D. ^c , Jun Hang,
6	Ph.D. ^d , Christian Fung, M.S. ^d , Hye Kyung Chung, Ph.D. ^d , Kristen K. Coleman, Ph.D. ^e , Nicolae Sapoval,
7 8	B.S. ^f , Todd Treangen, Ph.D. ^f , Irina Maljkovic Berry, Ph.D. ^d , Kristin Mullins, Ph.D. ^g , Matthew Frieman, Ph.D. ^c , Tianzhou Ma, Ph.D ^b , Donald K. Milton, M.D., Dr.P.H. ^a for the University of Maryland
9	StopCOVID Research Group*
10	1 1
11	^a Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental Health,
12	University of Maryland School of Public Health, College Park, Maryland, USA
13 14	^b Department of Epidemiology and Biostatistics, University of Maryland School of Public Health, College Park, Maryland, USA
15	^c Department of Microbiology and Immunology, University of Maryland School of Medicine,
16	Baltimore, Maryland, USA
17	^d Viral Diseases Branch, Walter Reed Army Institute for Research, Silver Spring, Maryland, USA
18 19	^e Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore ^f Department of Computer Science, Rice University, Houston, Texas, USA
20	^g Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA
21	
22	[*] Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive, College
23	Park, MD 20742 email: dmilton@umd.edu; phone: 301-405-0389 (Alternate: Dr. Filbert Hong, at the
24 25	same address, email <u>fhong@umd.edu</u> , phone: 301-405-4081)
23 26	Key words: SARS-CoV-2; exhaled breath aerosol; face masks; airborne infection; SARS-CoV-2
27	variants
28	Running Title: SARS-CoV-2 in Exhaled Aerosols
29 30	Ver Deinter
30 31	Key Points:Cases exhale infectious viral aerosols.
32	 SARS-CoV-2 is evolving toward more efficient airborne transmission.
33	 Loose-fitting masks significantly but moderately reduce viral RNA aerosol.
34	 Tight-fitting masks or respirators and ventilation/air cleaning are essential for worker protection
35	in public-facing or crowded indoor workplaces.
36	

38 39

40 Abstract

- 41
- Background: SARS-CoV-2 epidemiology implicates airborne transmission; mask source-control
 efficacy for, variant impact on, and infectiousness of aerosols are not well understood.
- 44 Methods: We recruited COVID-19 cases to give blood, saliva, mid-turbinate and fomite (phone) swabs,
- and 30-minute breath samples while vocalizing into a Gesundheit-II, with and without masks at up to
 two visits two days apart. We quantified and sequenced viral RNA, cultured virus, and assayed sera for
- 47 anti-spike and anti-receptor binding domain antibodies.
- 48 **Results:** We enrolled 61 participants with active infection, May 2020 through April 2021. Among 49
- 49 serone gative cases (mean days post onset 3.8 \pm 2.1), we detected SARS-CoV-2 RNA in 45% of fine (\leq 5
- 50 μ m), 31% of coarse (>5 μ m) aerosols, and 65% of fomite samples overall and in all samples from four
- 51 alpha variant cases. Masks reduced viral RNA by 48% (95% confidence interval [CI], 3 to 72%) in fine
- 52 and by 77% (95% CI, 51 to 89%) in coarse aerosols. The alpha variant was associated with a 43-fold
- 53 (95% CI, 6.6 to 280-fold) increase in fine aerosol viral RNA that remained a significant 18-fold (95%
- 54 CI, 3.4 to 92-fold) increase adjusting for viral RNA in saliva, in mid-turbinate swabs, and other potential
- 55 confounders. Two fine aerosol samples, collected days 2-3 post illness onset, while participants wore 56 masks, were culture-positive.
- 57 Conclusion: SARS-CoV-2 is evolving toward more efficient airborne transmission and loose-fitting
- 58 masks provide significant but only modest source control. Therefore, until vaccination rates are very
- 59 high, continued layered controls and tight-fitting masks and respirators will be necessary.
- 60

61 Introduction

62

The World Health Organization[1] and U.S. Centers for Disease Control and Prevention[2] recently 63 acknowledged the growing scientific consensus that inhalation exposure is an important route of SARS-64 65 CoV-2 transmission[3,4]. The totality of evidence from epidemiologic and outbreak investigations, combined with data on the size distribution of exhaled aerosols and corresponding quantitative models, 66 is compelling[4]. However, culture of the virus from exhaled aerosols, and direct measures of the 67 68 efficacy of face masks as viral aerosol source control when worn by actual patients have been lacking. 69 Previous reports of infectious virus [5,6] and viral RNA concentrations in room air [7,8] do not provide a 70 clear picture of how much virus infected persons shed into the air. These gaps lead to uncertainty in 71 estimates of exposure, derived from retrospective analysis of outbreaks[9]. New variants also appear 72 more transmissible, but more quantitative data is needed to discern what that means for implementing 73 effective non-pharmaceutical interventions – still a mainstay of infection protection.

74

75 We collected exhaled breath aerosol samples from polymerase chain reaction (PCR)-confirmed COVID-

76 19 cases infected with SARS-CoV-2, including alpha and earlier variants, circulating in a university

campus community using a Gesundheit-II (G-II) exhaled breath sampler[10,11]. We measured

78 concentrations of SARS-CoV-2 RNA and recovered infectious virus from respiratory swabs, saliva, and

aerosols, analyzed the effectiveness of face masks as source control, and examined the impact of the

80 alpha variant on aerosol shedding.

81 Materials and Methods

82

This study was approved by the University of Maryland Institutional Review Board and the Human
Research Protection Office of the Department of the Navy. Electronically signed informed consent was
obtained and questionnaire data were collected and stored with REDCap[12].

86

87 We recruited participants with active infection (defined as positive qRT-PCR for SARS-CoV-2 in 88 respiratory swab or saliva samples) from the University of Maryland College Park campus and 89 surrounding community though a) daily symptom reporting and weekly pooled saliva testing from a 90 cohort of 238 volunteers, b) direct recruiting of recently diagnosed cases targeting local clinics and 91 campus isolation facilities, and c) frequent testing of close contacts of cases for two weeks following last 92 contact. Recruited cases and close contacts completed online consents and a questionnaire (see 93 Supplemental Methods) before in-person confirmation of consent and specimen collection at the 94 University of Maryland School of Public Health. For contacts, we collected a blood specimen for 95 serology at the first visit and measured oral temperature, blood oxygen saturation (SpO₂), and collected 96 a mid-turbinate swab (MTS) from each nostril and a saliva sample, at approximately two-day intervals.

97

Cohort members with a positive saliva sample, recently-diagnosed cases, and contacts with a positive test during follow-up were invited for viral shedding assessment visits on two days separated by one day. Venous blood was collected at the first visit; MTS, saliva, phone/tablet swab, and 30-minute G-II exhaled breath samples were collected at each visit[10,11]. We asked participants to provide paired breath samples at each visit with the first collected while wearing a face mask and a second without a mask[13]. We tested the mask brought by the participant and a surgical mask that we provided, and randomized which was tested at the first and second visit to avoid a systematic order bias. Cases studied

105 before September 2020 were asked to repeat the alphabet three times within the 30-minute sampling

106 period, as previously described [13]. Subsequent cases were asked to shout "Go Terps" 30 times and sing "Happy Birthday" loudly three times at 5, 15, and 25 minutes into each 30-minute sampling period. 107 108 Participants with more severe symptoms sometimes opted to give only one 30-minute breath sample; for 109 these participants, sampling without a face mask was given priority.

- 110
- 111 Symptom evaluation

112 Symptoms were self-reported and measured on a scale of 0-3 and composite scores were sums of

113 individual symptom scores for systemic, gastrointestinal, lower respiratory, and upper respiratory

114 symptoms as previously described[10], see Supplementary Information [SI] for additional details.

- 115
- 116 Sample preparation

117 MTS and phone/tablet swabs were eluted in 1 mL of Universal Transport Media (BD). MTS from both 118 nostrils were combined. G-II coarse and fine aerosol samples were concentrated, resulting in a 1-mL 119 final sample volume as previously described.[10] One aliquot each of MTS and saliva samples were

120 kept at 4 °C for immediate gRT-PCR. All other aliquots were stored at -80 °C until further analysis.

- 121
- 122

Laboratory analyses

123 Specific laboratory analysis details can be found in the SI. Cohort saliva was processed using the 124 SalivaDirect method[14]. For all other samples, nucleic acids were extracted with MagMax Pathogen 125 RNA/DNA Kit (Applied Biosystems) on KingFisher Duo Prime (Thermo Scientific), following 126 manufacturer protocols specific to sample type. Viral RNA was detected and quantified using the 127 TagPath COVID-19 Real Time PCR Assay Multiplex and coinfection of samples was determined using the TagMan Array Card (both Thermo Scientific). RNA copy numbers are reported per mL for saliva 128 and per sample for all other sample types. The limit of detection (LOD) was 75 copies/sample and the 129 130 limit of quantification (LOQ) was 250 copies/sample (SI).

131

132 Viral infectivity was measured by first propagating virus on Vero E6 cells stably expressing TMPRSS2 133 then transferring the media to A549 cells stably expressing human ACE2 (A549-ACE2). Infected A549-ACE2 cells were quantified using immunofluorescence staining with anti-SARS-CoV-2 nucleocapsid 134 135 antibody (Sino Biological 40143-R004) and Hoechst 33342 (Invitrogen H3570), and imaging with a 136 Celigo Imaging Cytometer (Nexcelom) (Figures S1, S2). Plasma was analyzed for IgG, IgM, and IgA antibodies to SARS-CoV-2 using a modified protocol described by Stadlbauer et al., 2020[15]. MTS and 137 138 saliva samples were sequenced at the Walter Reed Army Institute for Research or the University of 139 Maryland Institute for Genome Sciences. SARS-CoV-2 lineages and mutations were determined using 140 PANGOLIN and Nextstrain tools[16,17].

- 141
- 142 Statistical analysis

143 We included analysis of all actively infected cases recruited from the campus and surrounding

community over the course of one year. To ensure comparability of with and without mask samples in 144 the analysis of mask efficacy, we included only paired same-day samples collected with and without a 145

- 146 face mask from the same person and controlled for numbers of coughs during each sampling session.
- 147
- Data curation, cleaning, analysis, and visualization were performed using R Studio and R (version 148
- 4.1.0)[18], with R packages lme4, lmec, and ggplot2[19]. We made group comparison between 149
- 150 seronegative and seropositive cases using two-sample t-test for continuous variables and Fisher's exact
- test for categorical variables. To handle censored observations below the limit of detection, we applied 151

152 linear mixed-effect models with censored responses[20,21] and included nested random effects of

samples within each case, and replicates within samples. The geometric means and standard deviations

of viral RNA copy numbers for all sample types and the effect of the predictors of viral RNA shedding

155 were estimated from the model. Deidentified data and code for the accepted manuscript will be made 156 available on github.

157

158 **Results**

159

Sixty-one people with active SARS-CoV-2 infection (recent onset and positive PCR for MTS or saliva) were enrolled in exhaled breath testing: 3 from a weekly saliva testing cohort, 43 from among 55 recently diagnosed COVID-19 cases, and 15 from among 62 contacts of cases followed to detect early onset of infection (Figure S3). Eight people (13%) with active infection had either IgM or IgG antibodies to SARS-CoV-2 spike protein at the first breath testing visit and four were unable to give a venous blood sample.

166

167 The 57 participants with known serologic status at the time of breath sampling (49 seronegative, 8 168 seropositive) were enrolled from zero to 12 days post onset of symptoms or first positive test (Table 1, 169 Figure S4). The seronegative cases included all participants with prior singing experience and alpha 170 variant infection – there were no other significant differences between seropositive and seronegative 171 groups including frequency of loss of taste/smell, other symptoms, temperature and oxygen saturation. 172 All cases were asymptomatic or mild at the time of study. No volunteer was taking antiviral medication 173 et the time of hearth generale callection and an an infection providentified.

at the time of breath sample collection and no co-infections were identified.

175 Seronegative cases

176 Among seronegative participants, 4 (8%) were infected with the alpha and none with delta or other 177 variants associated with increased transmissibility[22] (Table S1). Symptoms tended to be more 178 pronounced at the first shedding visit and two participants were febrile at the second shedding visit 179 (Figures S5-S6). Each of the 4 seronegative alpha variant cases had detectable concentrations of viral 180 RNA in all MTS, saliva, fomite, and aerosol samples (Table 2). Among the remaining seronegative 181 participants, we detected viral RNA in all MTS, 99% of saliva, 49% of fomite, 19% of coarse-, and 31% 182 of fine-aerosol samples. The geometric mean concentrations of viral RNA were significantly greater for 183 all sample types collected from alpha variant cases.

- 184
- 185 Exhaled breath viral RNA from seronegative cases without masks

186 Viral RNA content of 30-minute breath aerosol samples was similar to the amount of RNA recovered 187 from participants' mobile phones (Table 2). The frequency of detection of viral RNA in aerosols was 188 greatest 2-5 days post onset of symptoms or first positive test (Figure S7) but was not a significant 189 predictor of the quantity of viral RNA in the aerosols (Table 3). Viral RNA in MTS and saliva were 190 moderately correlated (Figure S8: ρ =0.46) but only RNA in MTS was a strong predictor of viral load in 191 aerosols (Table 3, Figures S9, S10). The quantity of viral RNA in the fine-aerosol fraction was 1.9-fold 192 (95% confidence interval [CI] 1.2 to 2.9-fold) greater than in the coarse-aerosol fraction (not shown).

193

194 Effect of alpha variant infection on viral RNA shedding from seronegative cases

195 Alpha variant infection was associated with significantly greater amounts of viral RNA shedding than

196 infection with earlier strains and variants. In bivariate analyses of samples collected without masks

197 (Tables 3 and S3), the alpha variant was associated with significantly greater viral RNA shedding than wild-type and other variants not associated with increased transmissibility. Fine-aerosol shedding 198 remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after 199 200 adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling sessions, and symptoms (Table 3). We also analyzed the impact of alpha variants on shedding using the 201 larger data set, including samples collected with and without masks. After controlling for the effect of 202 masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold 203 204 (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-205 aerosol RNA shedding (Table 3).

206

207 Effect of masks on viral RNA shedding from seronegative cases

We observed statistically significant reductions in aerosol shedding after adjusting for number of coughs 208 during sampling sessions: 77% (95% CI, 51% to 89%) reduction for coarse and 48% (95% CI, 3% to 209 72%) for fine aerosols (Figure 1). Analysis of the interaction of masks and the alpha variant (Table 3) 210 confirmed that mask performance was not significantly different for alpha variant infections. The types 211 212 of face masks brought by participants varied and progressed from single-layer homemade and an imported decorative scarf-mask early in the study to homemade and commercial double-layer cloth 213 masks, surgical masks, double masks, and a KN95 over the course of the year (Table S4). We did not 214 215 observe a significant difference between surgical masks and a composite of the various cloth masks studied (Table S5). 216

- 217
- 218 Seropositive cases

Eight participants had antibodies to SARS-CoV-2 spike protein at the time of breath sample collection.
Seropositive cases tended to cough more than seronegative cases (Table 1) but none of the exhaled
aerosol samples from seropositive cases had detectable viral RNA (Table S6).

- 222
- 223 Virus cultures

224 Among samples subjected to virus culture, we detected infectious virus (Figure S2) in 50 (68%) of 73 MTS and 20 (32%) of 62 saliva samples from seronegative participants (Figure 2, Table S2a). The RNA 225 concentration associated with a 50% probability of a positive culture was 7.8 x 10⁵ for MTS and 5.2 x 226 10⁶ for saliva (Figure S11, Table S7). None of the 75 fine-aerosol samples collected while not wearing 227 face masks were culture-positive. Two (3%) of the 66 fine-aerosol samples collected from participants 228 while wearing face masks were culture-positive, including one from a person infected with the alpha 229 variant 2 days post onset and one from a person with a Nextstrain clade 20G virus 3 days post onset. 230 231 Fomite and coarse-aerosol samples subjected to culture were negative.

232 Discussion

Alpha variant infection yielded one to two orders of magnitude more viral RNA in exhaled breath when compared with earlier strains and variants not associated with increased transmissibility. Our observation of increased aerosol shedding, even after controlling for the increased amounts of viral RNA in the nose and mouth, suggests that evolutionary pressure is selecting for SARS-CoV-2 capable of more efficient airborne transmission.

- 237 238
- 239 We recovered infectious virus from two exhaled breath fine-aerosol samples, approximately two-thirds
- of MTS, and one-third of saliva samples. Logistic regression analysis of the MTS and saliva samples
- suggests that there is a small but measurable probability that each RNA copy represents an infectious

242 viral particle consistent with previous dose-response models of infectious viruses[23]. The probability of detecting infectious virus in our cell culture system may be as high as 10⁻⁴ per RNA copy in saliva 243 samples with 10^2 copies. We recovered infectious virus from one of the two fine-aerosol samples 244 245 with $>10^4$ RNA copies per sample, where the estimated probability of a positive culture was 8% per sample, based on the regression model. The other culture-positive aerosol sample was one of 98 aerosol 246 247 samples below the 75-copy limit of detection for RNA. This observation is consistent with a previous 248 report of infectious SARS-CoV-2 in an aerosol sample with very low RNA copy numbers[5], and may 249 suggest that virus particles in respiratory aerosols contain fewer defective virions than MTS, or that the 250 is less likely to interfere with viral cell attachment and entry than are nasal secretions and saliva. It fluid 251 is likely that human airway epithelium is more susceptible to infection than laboratory cell cultures[24].

The assorted face masks used by the study volunteers produced significant, albeit modest, reductions in 253 the amount of viral RNA in exhaled breath, supporting their use as source control. Consistent with 254 255 previous studies of influenza, SARS-CoV-2 viral RNA was shed more abundantly in fine than coarse aerosol and masks were more effective at blocking release of coarse aerosol[10,13,25,26]. The 256 257 effectiveness of face masks for blocking release of fine aerosol (1.9-fold) was similar to the effectiveness we previously reported for influenza (2.8-fold). However, the 4.3-fold (or 77%) reduction 258 in coarse aerosol was significantly less than the 25-fold reduction previously observed for influenza 259 shedding[13]. This discrepancy likely arose because the more vigorous and extended vocalizations in the 260 current study would be expected to maximize leakage around loose-fitting face masks. Face masks 261 worked equally well for containing alpha variant and "wild-type" aerosol shedding. 262

263

252

Viral RNA aerosol collected from 22 COVID-19 patients in Singapore using a G-II measured similar 264 RNA copy numbers and overall rates of positive breath samples (59% versus 51% here) during singing 265 and loud talking as observed here[27]. A majority (68%) of the cases studied in Singapore were infected 266 by variants associated with increased transmissibility, while 18% of infections were not variants of 267 concern or interest, and each case was sampled on only one day. By comparison, our sample included 268 'wild-type" infections and sampling days per person allowing analysis of the impact of variants on 269 270 shedding. One delta variant was studied in Singapore and none in this study. The shedding rates detected using the G-II in both studies, however, were lower than those reported by Ma et al. using a sampler that 271 requires subjects to blow through a narrow straw[28]. Ma et al. and our data are in agreement that 272 among persons infected with "wild-type" strains, a minority (26% and 31%, respectively) shed 273 detectable levels of viral RNA into aerosols. However, our data on alpha variant infections and the data 274 from Singapore suggest that this is changing and most cases may now be shedding viral aerosols more 275 276 frequently. We have yet to enroll cases with the delta variant and study them using the Maryland protocol to test the expectation, based on our current findings, that delta will be associated with an 277 additional large increase in aerosol shedding. 278

279

Our study had several limitations. Although we attempted to identify and test cases early through weekly 280 testing of a cohort and intensive follow-up of close contacts, most cases were still studied several days 281 after onset of symptoms or first positive test. This likely resulted in missing the most contagious 282 period[29,30]. Furthermore, all cases were mild at the time of testing and only two went on to have 283 moderate severity and require hospitalization. As a result, our data may not represent the full spectrum 284 of shedding. The types of face masks worn by participants changed over the course of the study, as did 285 the quality of surgical masks that we could purchase. Therefore, we cannot report on the efficacy of 286 specific loose-fitting masks. This work does, however, provide information on the average amount of 287

source control provided by community masking. Finally, logistical considerations required that we
 freeze samples between collection and culture, with potential loss of infectiousness, especially for dilute
 aerosol specimens.

291

Overall, our results demonstrate that people with mild or asymptomatic SARS-CoV-2 infections 292 293 released infectious aerosols in their exhaled breath. Face masks provided significant source control 294 suggesting that community-wide masking even with loose-fitting masks can reduce viral aerosols in 295 indoor air by half, making a significant contribution to reducing the spread of COVID-19. Our data also 296 suggest that the virus is evolving toward more effective dissemination through aerosols and demonstrate 297 that infectious virus can escape from loose-fitting masks. With the dominance of newer, more contagious variants than those we studied, increased attention to improved ventilation, filtration, air 298 299 sanitation, and use of high-quality tight-fitting face masks or respirators (e.g., ASTM F3502-21 facecoverings or NIOSH approved N95 filtering face-piece and elastomeric respirators) for respiratory 300 301 protection will be increasingly important for controlling the pandemic. This will be especially true where vaccination rates are low, vaccine is not available, and for people with poor immune responses or 302 303 waning immunity. Therefore, our data support community mask mandates and tight-fitting masks or respirators for workers in healthcare but also in all workplaces where people are sharing indoor air or 304 have frequent public contact. 305

- 306
- 307
- 308

309 Acknowledgements

310 We thank Dr. Jacques Ravel, Dr. Luke Tallon, and the Institute of Genome Sciences at the University of

311 Maryland School of Medicine for performing deep sequencing of SARS-CoV-2 samples. We also thank

312 Dr. Jamal Fadul and his clinic in College Park, Maryland, for assistance in recruiting study participants.

313 Disclaimers and Funding

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. The View(s) expressed are those of the authors and do not necessarily reflect the official views of the Department of Health and Human Services, the Departments of the Army, Navy or Air Force, the Department of Defense, or the U.S. Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these agencies and no official endorsement should be inferred.

321

This work was supported by Prometheus-UMD, sponsored by the Defense Advanced Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-4015. This work was also supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS), Grant Number HHSN272201400008C, the Centers for Disease Control and Prevention, Contract Number 200-2020-09528. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these funding agencies and no official endorsement should be inferred.

- 330 This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a generous gift
- from The Flu Lab (https://theflulab.org). The funders had no role in study design, data collection,
- analysis, decision to publish, or preparation of the manuscript.

333

335 References

- World Health Organization. Coronavirus disease (COVID-19): How is it transmitted? 2021.
 Available at: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-ittransmitted. Accessed 31 May 2021.
- CDC. Scientific Brief: SARS-CoV-2 Transmission. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html.
 Accessed 8 May 2021.
- Morawska L, Milton DK. It Is Time to Address Airborne Transmission of Coronavirus Disease 2019
 (COVID-19). Clin Infect Dis 2020; 71:2311–2313.
- Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet 2021; 397:1603–1605.
- 5. Lednicky JA, Lauzardo M, Fan ZH, et al. Viable SARS-CoV-2 in the air of a hospital room with
 COVID-19 patients. Int J Infect Dis 2020; 100:476–482.
- Lednicky JA, Lauzardo M, Alam MdM, et al. Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. Infectious Diseases (except HIV/AIDS), 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.01.12.21249603. Accessed 1 February 2021.
- 7. Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by SARS-CoV-2
 in hospital rooms of infected patients. Nat Commun 2020; 11:2800.
- Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals.
 Nature 2020; 582:557–560.
- Miller SL, Nazaroff WW, Jimenez JL, et al. Transmission of SARS-CoV-2 by inhalation of
 respiratory aerosol in the Skagit Valley Chorale superspreading event. Indoor Air 2020;
- 10. Yan J, Grantham M, Pantelic J, et al. Infectious virus in exhaled breath of symptomatic seasonal
 influenza cases from a college community. Proc Natl Acad Sci USA 2018; 115:1081–1086.
- 11. McDevitt JJ, Koutrakis P, Ferguson ST, et al. Development and Performance Evaluation of an
 Exhaled-Breath Bioaerosol Collector for Influenza Virus. Aerosol Sci Technol 2013; 47:444–451.
- 12. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
 community of software platform partners. Journal of Biomedical Informatics 2019; 95:103208.
- Milton DK, Fabian MP, Cowling BJ, Grantham ML, McDevitt JJ. Influenza virus aerosols in human
 exhaled breath: particle size, culturability, and effect of surgical masks. PLoS Pathog 2013;
 9:e1003205.
- Vogels CBF, Brackney D, Wang J, et al. SalivaDirect: Simple and sensitive molecular diagnostic
 test for SARS-CoV-2 surveillance. Infectious Diseases (except HIV/AIDS), 2020. Available at: http://medrxiv.org/lookup/doi/10.1101/2020.08.03.20167791. Accessed 17 August 2020.

369	15. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed
370	Protocol for a Serological Assay, Antigen Production, and Test Setup. Current Protocols in
371	Microbiology 2020; 57:e100.
372	16. O'Toole Á, Hill V, McCrone JT, Scher E, Rambaut A. cov-lineages/pangolin. CoV-lineages, 2021.
373	Available at: https://github.com/cov-lineages/pangolin. Accessed 15 July 2021.
374	 Trevor Bedford, Richard Nehe, James Hadfield, et al. Nextstrain SARS-CoV-2 resources. 2020.
375	Available at: https://nextstrain.org/sars-cov-2/. Accessed 29 July 2021.
376	 R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R
377	Foundation for Statistical Computing, 2021. Available at: https://www.R-project.org/.
378	 Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2nd ed. Springer International
379	Publishing, 2016. Available at: https://www.springer.com/gp/book/9783319242750. Accessed 11
380	June 2020.
381	 Vaida F, Fitzgerald AP, DeGruttola V. Efficient Hybrid EM for Linear and Nonlinear Mixed Effects
382	Models with Censored Response. Comput Stat Data Anal 2007; 51:5718–5730.
383	 Vaida F, Liu L. Fast Implementation for Normal Mixed Effects Models With Censored Response. J
384	Comput Graph Stat 2009; 18:797–817.
385	22. CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available at:
386	https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed 12 July 2021.
387	 Haas CN. Estimation of risk due to low doses of microorganisms: a comparison of alternative
388	methodologies. Am J Epidemiol 1983; 118:573–582.
389	 Pohl MO, Busnadiego I, Kufner V, et al. SARS-CoV-2 variants reveal features critical for
390	replication in primary human cells. PLoS Biol 2021; 19:e3001006.
391	 Lindsley WG, Noti JD, Blachere FM, et al. Viable influenza A virus in airborne particles from
392	human coughs. J Occup Environ Hyg 2015; 12:107–113.
393 394	26. Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 2020 ; 26:676–680.
395	 Coleman KK, Tay DJW, Tan KS, et al. Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted
396	by COVID-19 Patients while Breathing, Talking, and Singing. medRxiv 2021;
397	:2021.07.15.21260561.
398	 Ma J, Qi X, Chen H, et al. COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per
399	hour. Clin Infect Dis 2020; Available at: https://academic.oup.com/cid/advance-
400	article/doi/10.1093/cid/ciaa1283/5898624.
401	 He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-
402	19. Nature Medicine 2020 ; 26:672–675.

30. Yang Q, Saldi TK, Gonzales PK, et al. Just 2% of SARS-CoV-2-positive individuals carry 90% of
 the virus circulating in communities. Proc Natl Acad Sci U S A 2021; 118:e2104547118.

Tables

Table 1. Characteristics of the study population

	Antibody negative	Antibody positive	All with serologic tests	P-value ^a
Number of participants	49	8	57	-
Number of exhaled breath sample visits ^b	78	15	93	-
Female, N (%)	18 (37)	2 (25)	20 (35)	0.70
Age, mean years ± SD	23.7 ± 9.5	24.9 ± 8.4	23.8 ± 9.3	0.73
Age group, N (%)				-
<18	1 (2)	0 (0)	1 (2)	
18-45	45 (92)	8 (100)	53 (93)	
>45	3 (6)	0 (0)	3 (5)	
White, N (%)	40 (82)	5 (62)	45 (79)	0.16
BMI, mean ± SD	24.6 ± 4.5	27.3 ± 4.8	25 ± 4.6	0.12
Chronic respiratory illness ^c N (%)	12 (24)	1 (12)	13 (23)	0.67
Ever smoker N (%)	2 (4)	1 (12)	3 (5)	0.37
Has taken singing lessons/part of a choir N (%)	4 (8)	0 (0)	4 (7)	-
Alpha Variant N (%)	4 (8)	0 (0)	4(7)	_
Days post onset ^d mean ± SD (range)	3.8 ± 2.1 (Day 1 to 10)	5.9 ± 3.8 (Day 0 to 12)	4.1 ± 2.5 (Day 0 to 12)	0.18
Coughs per 30 min, mean ± SD (range)	1 ± 3 (0-17)	3 ± 8 (0-24)	1 ± 4 (0-24)	0.098
Loss of taste/smell N (%)	13 (27)	4 (50)	17 (30)	0.22
Median upper respiratory symptoms (IQR) ^e	2 (1 - 3)	3 (1.5 - 4)	2 (1 - 3)	0.17
Median lower respiratory symptoms (IQR)	0 (0 - 1.2)	0 (0 - 1)	0 (0 - 1)	0.82
Median systemic symptoms (IQR)	1 (0 - 3)	1 (0 - 2.5)	1 (0 - 3)	0.60
Median gastrointestinal symptoms (IQR)	0 (0 - 1)	0 (0)	0 (0-1)	0.36
Temperature, mean Celsius ± SD	37.2 ± 0.4	37.2 ± 0.2	37.2 ± 0.3	0.80
Oxygen saturation (SpO ₂), mean \pm SD	97.9 ± 1	97.5 ± 1.1	97.8 ± 1	0.25

409 BMI, Body mass index; IQR, Interquartile range;

- 410 ^a Group comparisons were made between antibody negative and positive cases using two-sample t-test for continuous variables and
- 411 Fisher's exact test for categorical variables.
- 412 ^b 57 volunteers provided breath samples and sera at the initial shedding assessment visit; 34 of them provided exhaled breath samples
- 413 at the 2^{nd} shedding assessment visit approximately 2 days later; four volunteers who did not provide sera at the first visit were
- 414 excluded.
- 415 ^c Chronic respiratory illness = volunteers with any Chronic obstructive pulmonary disease, Asthma, Other lung diseases.
- 416 ^d Days since start of symptoms or first positive test if asymptomatic or presymptomatic to first breath sample; 3 subjects reported no 417 symptoms.
- ^e Symptoms at the time of each sample collection visit. Sixteen symptoms were rated from 0 to 3 with a maximum possible composite
- 419 score of 15 for upper respiratory, 9 for lower respiratory, 12 for systemic symptoms and 12 for gastrointestinal symptoms.

Sample Type	Variant	Case ^a	Cases with ≥1 positive sample ^ь N (%)		Samples	Positive Samples [。] N (%)		GM (95% CI) ^d	Maximum RNA copiesº
			≥LOD	∠LOQ		≥LOD	≥LOQ		
Mid-turbinate	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	3.8 x 10 ⁸ (3.3 x 10 ⁸ , 4.4 x 10 ⁸)	2.9 x 10 ⁹
swab	Other	45	45 (100)	45 (100)	74	74 (100)	73 (99)	3.8 x 10 ⁶ (1.4 x 10 ⁶ , 1.0 x 10 ⁷)	5.1 x 10 ⁹
Saliva	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	1.9 x 10 ⁷ (2.7 x 10 ⁶ , 1.3 x 10 ⁸)	5.2 x 10 ⁸
Saliva	Other	45	44 (98)	44 (98)	74	73 (99)	70 (95)	2.1 x 10 ⁵ (8.1 x 10 ⁴ , 5.4 x 10 ⁵)	3.9 x 10 ⁸
Foreita	Alpha	4	4 (100)	4 (100)	6	6 (100)	4 (67)	560 (530, 590)	1.7 x 10 ⁴
Fomite	Other	45	28 (62)	14 (31)	74	36 (49)	17 (23)	46 (17, 120)	1.2 x 10 ⁶
Coarse	Alpha	4	4 (100)	2 (50)	6	6 (100)	3 (50)	140 (28, 730)	5.1 x 10 ⁴
(>5 µm) Aerosol	Other	45	11 (24)	5 (11)	72	14 (19)	5 (7)	7 (3.2, 15)	2.6 x 10 ⁴
Fine	Alpha	4	4 (100)	3 (75)	6	6 (100)	4 (67)	580 (450, 740)	5.4 x 10 ⁴
(≤5 µm) Aerosol	Other	45	18 (40)	8 (18)	72	22 (31)	9 (12)	18 (9.1, 34)	2.8 x 10 ³

Table 2. Viral RNA from cases	seronegative for SARS-CoV-2 antibodies at the first assessment

^a Participants with a mid-turbinate or saliva samples positive for SARS-CoV-2 viral RNA by qRT-PCR and seronegative for SARS-CoV-2 spike protein antibody at enrollment and who provided at least one 30-minute sample of exhaled breath.

^b Number of participants with at least one sample \geq limit of detection (LOD) or \geq limit of quantification (LOQ) (Supplementary.

^c Samples positive and \geq LOD had at least one replicate with confirmed amplification after inspection and quality control (LOD ~75 RNA copies with 95% probability of detection) and \geq LOQ if the mean of replicate assays was \geq 250 RNA copies.

^d GM = geometric mean. The GMs were computed, accounting for samples below the LOD, using a linear mixed-effects model for censored responses (R Project LMEC package) using data for all samples of each sample type with nested random effects of samples within study participant.

^e The largest quantity of RNA copies detected based on the mean of replicates qRT-PCR aliquots.

	Coars	se Aerosol (>	⊳5 µm)	Fine Aerosol (≤5 µm)			
	Without Face Mask N=49, n=78ª		Paired ± Mask N=46, n = 69	Without F N=49	Paired ± Mask N=46, n = 69		
	Unadjusted	Adjusted ^b	Estimate ^c	Unadjusted	Adjusted	Estimate	
Alpha Variant	67 (6.7, 660)	3.6 (0.35, 36)	100 (16, 650)	43 (6.6, 280)	18 (3.4, 92)	73 (15, 350)	
Face mask	-	-	0.23 (0.11, 0.49)	-	-	0.52 (0.28, 0.97)	
Age	$1.4 \\ (0.44, 4.4)$	-	-	1.7 (0.74, 3.7)	1.7 (1, 2.8)	-	
Day post onset ^d	0.79 (0.53, 1.2)	-	-	0.97 (0.76, 1.2)	-	-	
Log mid- turbinate swab	480 (40, 5700)	36 (3.5, 370)	-	13 (4.3, 42)	7.3 (2.5, 21)	-	
Log saliva	4.6 (1.4, 15)	1.5 (0.55, 4.3)	-	2.8 (1.2, 6.5)	0.96 (0.47, 2)	-	
Number of coughs	1.2 (0.92, 1.5)	1.2 (1, 1.5)	1 (0.93, 1.2)	1.2 (0.96, 1.5)	1.2 (1, 1.3)	1.1 (1, 1.3)	
Upper respiratory symptoms	2.4 (0.91, 6.1)	-	-	1.7 (0.83, 3.6)	0.75 (0.44, 1.3)	-	
Lower respiratory symptoms	0.99 (0.36, 2.7)	0.4 (0.13, 1.2)	-	0.64 (0.3, 1.4)	-	-	
Gastrointestinal symptoms	2.3 (1.1, 5.2)	1.2 (0.55, 2.4)	-	1.7 (0.94, 3.2)	1 (0.61, 1.7)	-	
Systemic symptoms	5.7 (2.5, 13)	2.4 (0.97, 6.1)	-	2.1 (1.1, 4)	1.1 (0.59, 2)	-	
Alpha Variant x Face mask	-	_	0.62 (0.15, 2.7)	-	-	0.7 (0.2, 2.4)	


Table 3. Predictors of viral RNA shedding among seronegative participants

Effect estimates and their 95% confidence intervals are shown as the ratio of RNA copy number of samples: with alpha variant to without alpha variant, with mask to without mask, or as the fold-increase in RNA copy number for a 10-year increase in age, 1-day increase in day post-symptom onset, and an interquartile range change in symptom scores, mid-turbinate swab and saliva RNA copy number. All

analyses were controlled for random effects of subject and sample nested within subjects and for censoring by the limit of detection using a linear mixed-effects model for censored responses (R Project lmec-package).


- ^a N = Number of participants, n = number of samples for without face mask analysis and number of pairs of same day with and without face masks samples for paired analysis of the effect of face masks.
- ^b The adjusted estimates accounted for potential covariates resulting in greater than 10% change in the estimates of the main exposure variable "Alpha variant"
- ^c The effect of mask on samples adjusted for Alpha variant and number of coughs counted during sample collection
- ^d Days since start of symptoms or first positive test if asymptomatic or presymptomatic to breath sample; 2 subjects had no symptoms

FIGURES



with mask I TRUE I FALSE

Figure 1. Viral RNA shedding in paired with and without face mask samples. Viral RNA measured during 69 same-day paired sampling events with and without mask from 46 seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained in 30-minute sampling durations. "+mask" = sample collected while wearing a face mask. MTS = mid-turbinate swab, Fomite = swab of participant's mobile phone.



Culture status I negative I positive

Figure 2. Viral RNA content and culture results of samples from all sampling events for seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained during 30-minute sampling events and included unpaired with and without face mask samples. Five fine aerosol samples with face mask and three fomite samples were not available for culture. A subset of MTS, saliva, and coarse aerosol samples were subjected to culture. MTS = mid-turbinate swab, Fomite = swab of participant's mobile phone.